MyCreds® Reaches Majority Adoption across Canada's Public Colleges, Institutes, Universities
'As Canada's nonprofit, sector-governed digital credential network, this achievement is a powerful endorsement of the trust, collaboration, and shared vision we hold with our institutional partners,' said Jodi Tavares, Executive Director of MyCreds I MesCertif. 'Together, we are transforming how learners, employers, and institutions connect through secure, portable, and instantly verifiable digital credentials.'
The MyCreds platform provides Canadian learners and credential holders with:
Secure, bilingual digital and web wallet to carry transcripts, diplomas, certificates, micro-credentials, and badges
Instant, paperless sharing with employers, institutions, government, and licensing bodies
Confidence that their data is protected under Canadian and provincial privacy and data residency standards
For institutions, MyCreds offers a fully auditable, standards-based system to issue, manage, and revoke credentials, improving efficiency, reducing costs, and supporting learner mobility across Canada and internationally.
MyCreds is Canada's official digital credentialing network, owned by the Association of Registrars of the Universities and Colleges of Canada (ARUCC). As a nonprofit-led national trust framework, MyCreds empowers institutions, organizations and issuing bodies to deliver secure, portable digital credentials to millions of learners.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Star
a day ago
- The Star
A few of Stride's ‘gadgets'
HOW does the Science and Technology Research Institute for Defence (Stride) envision the modernisation of Malaysia's military capabilities – such as through robotics, aerospace, or advanced materials – translating into tangible operational advantages for the country's armed forces in the coming decade? Stride director-general Nor Azlan Mohd Ramli outlines several key initiatives that cover operations in the air, on the ground and at sea as part of the Malaysia's 'Future Force' concept. He says among the key initiatives are Unmanned Ground Vehicles (UGV), co-developed with local industry, which supports missions ranging from surveillance and logistics to potential combat operations. 'Future enhancements will incorporate swarm capabilities and advanced sensor suites.' And apart from the use of Unmanned Aerial Vehicles (UAV) as border monitoring and in tactical combat missions, in the maritime domain, Stride is developing unmanned maritime systems to conduct mine detection, coastal patrols and anti-piracy operations, expanding Malaysia's autonomous maritime capabilities. At the same time, Nor Azlan says, to complement those efforts, innovations in materials science are also underway. 'The development of lightweight composite materials for military application aims to increase durability, extend platform lifespans, and reduce maintenance costs. For instance, in the field of fabric technology, Stride has developed TropiKamo®, a near-infrared (NIR) camouflage fabric meticulously designed for optimal performance in tropical climates. Engineered to provide effective concealment across both the visible and infrared spectrums, this advanced material significantly enhances stealth capabilities in Malaysia's jungle and semi-urban operational environments, says Nor Azlan. Meanwhile, also in place is Stride's Centre of Excellence for Electromagnetic Compatibility (EMC) Technology, which will serve as a national testing hub to certify systems to international standards, improve resilience to electromagnetic interference (EMI), and support the safe integration of electronic and weapon systems. 'By reducing reliance on foreign testing centres, the EMC facility will also help elevate locally developed defence technologies to export-ready standards, thereby reinforcing industrial empowerment and technological independence.' Nor Azlan says between 2025 and 2035, Stride's initiatives are set to deliver measurable impact for the Malaysian Armed Forces (MAF), including improved operational efficiency, cost savings and enhanced deterrence. 'Upgraded C4ISR (Command, Control, Communications, Computers, Intelligence, Surveillance, and Recon-naissance) systems will enable seamless coordination across all operational domains.' He stresses that the MAF are expected to possess fully integrated, rapid-response capabilities, enabling effective action against simultaneous threats across multiple operational domains. 'Unmanned systems are anticipated to assume a significant share of intelligence, surveillance, reconnaissance (ISR), and logistics roles, potentially reducing personnel casualties in high-risk environments. Overall, Nor Azlan says indigenous UAVs and UGVs, coupled with strengthened cyber defence capabilities, will reinforce Malaysia's deterrence posture, supporting missions against piracy, smuggling and territorial incursions. 'Locally developed and tested advanced materials will ensure system reliability in Malaysia's tropical operating environments. 'These advancements will also increase Malaysia's participation in regional initiatives such as Asean and Five Power Defence Arrangement (FPDA) exercises, enhancing defence diplomacy and regional stability.'
Malaysian Reserve
2 days ago
- Malaysian Reserve
CIBC Asset Management announces CIBC ETF cash distributions for July 2025
TORONTO, July 25, 2025 /CNW/ – CIBC (TSX: CM) (NYSE: CM) – CIBC Asset Management Inc. today announced the July 2025 cash distributions for CIBC ETFs and ETF Series of the CIBC Fixed Income Pools, which distribute monthly and quarterly. Unitholders of record on July 31, 2025, will receive cash distributions payable on August 6, 2025. Details of the final 'per unit' distribution amounts are as follows: CIBC ETF Ticker Symbols Exchange Cash Distribution Per Unit ($) CIBC Canadian Government Long-Term Bond ETF CALB TSX $0.040 CIBC USD Premium Cash Management ETF (USD)* CUSD.U TSX $0.20 CIBC Premium Cash Management ETF CCAD TSX $0.13 CIBC Active Investment Grade Corporate Bond ETF CACB TSX $0.074 CIBC Active Investment Grade Floating Rate Bond ETF CAFR TSX $0.056 CIBC Flexible Yield ETF (CAD-Hedged) CFLX TSX $0.077 CIBC Conservative Fixed Income Pool ETF CCNS TSX $0.062 CIBC Core Fixed Income Pool ETF CCRE TSX $0.063 CIBC Core Plus Fixed Income Pool CPLS TSX $0.075 CIBC Canadian Bond Index ETF CCBI TSX $0.048 CIBC Canadian Short Term Bond Index ETF CSBI TSX $0.050 CIBC Global Bond ex-Canada Index ETF (CAD-Hedged) CGBI TSX $0.041 CIBC Sustainable Canadian Core Plus Bond Fund CSCP CBOE $0.057 CIBC Qx Canadian Low Volatility Dividend ETF CQLC CBOE $0.069 CIBC Qx U.S. Low Volatility Dividend ETF CQLU CBOE $0.032 CIBC Qx International Low Volatility Dividend ETF CQLI CBOE $0.056 CIBC 2025 Investment Grade Bond Fund — ETF Series CTBA CBOE $0.030 CIBC 2026 Investment Grade Bond Fund — ETF Series CTBB CBOE $0.029 CIBC 2027 Investment Grade Bond Fund — ETF Series CTBC CBOE $0.036 CIBC 2028 Investment Grade Bond Fund — ETF Series CTBD CBOE $0.035 CIBC 2029 Investment Grade Bond Fund — ETF Series CTBE CBOE $0.045 CIBC 2030 Investment Grade Bond Fund — ETF Series CTBF CBOE $0.038 CIBC 2025 U.S. Investment Grade Bond Fund — ETF Series (USD)* CTUC.U CBOE $0.018 CIBC 2026 U.S. Investment Grade Bond Fund — ETF Series (USD)* CTUD.U CBOE $0.024 CIBC 2027 U.S. Investment Grade Bond Fund — ETF Series (USD)* CTUE.U CBOE $0.027 CIBC Income Advantage Fund ETF CCLO CBOE $0.085 * Cash distribution per unit ($) amounts are USD for CUSD.U, CTUC.U, CTUD.U, and CTUE.U CIBC ETFs are managed by CIBC Asset Management Inc., a subsidiary of Canadian Imperial Bank of Commerce. Commissions, management fees and expenses all may be associated with investments in exchange traded funds (ETFs). Please read the CIBC ETFs prospectus or ETF Facts document before investing. To obtain a copy, call 1-888-888-3863, ask your advisor or visit ETFs are not guaranteed, their values change frequently, and past performance may not be repeated. CIBC ETFs are offered by registered dealers. Morningstar® Canada Core Bond Index™, Morningstar Canada 1-5 Year Core Bond Index and Morningstar® Global ex-Canada Core Bond Hedged CAD Index™, are trademarks or service marks of Morningstar, Inc., and have been licensed for use for certain purposes by CIBC Asset Management. CIBC Canadian Bond Index ETF, CIBC Canadian Short-Term Bond Index ETF and CIBC Global Bond ex-Canada Index ETF (CAD Hedged), are not sponsored, endorsed, sold or promoted by Morningstar, and Morningstar makes no representation regarding the advisability of investing in the CIBC Canadian Bond Index ETF, CIBC Canadian Short-Term Bond Index ETF and CIBC Global Bond ex-Canada Index ETF (CAD-Hedged). About CIBC CIBC is a leading North American financial institution with 14 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world. Ongoing news releases and more information about CIBC can be found at About CIBC Asset Management CIBC Asset Management Inc. (CAM), the asset management subsidiary of CIBC, provides a range of high-quality investment management services and solutions to retail and institutional investors. CAM's offerings include: a comprehensive platform of mutual funds, strategic managed portfolio solutions, discretionary investment management services for high-net-worth individuals, and institutional portfolio management. CAM is one of Canada's largest asset management firms, with over $227 billion in assets under administration as of June 2025.
Malaysian Reserve
2 days ago
- Malaysian Reserve
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:
